Valuation: Eli Lilly and Company

Market Cap 1,133B 1,009B 934B 846B 1,593B 106,888B 1,612B 11,204B 4,396B 56,184B 4,249B 4,161B 179,034B P/E 2026 *
36.7x
P/E 2027 * 28.3x
Enterprise Value 1,159B 1,033B 957B 866B 1,631B 109,410B 1,650B 11,469B 4,500B 57,510B 4,349B 4,259B 183,258B EV / Sales 2026 *
13.1x
EV / Sales 2027 * 11.1x
Free-Float
99.84%
Yield 2026 *
0.54%
Yield 2027 * 0.61%
1 day+0.73%
1 week+5.13%
Current month+9.82%
1 month+9.09%
3 months+8.11%
6 months+40.72%
Current year+18.24%
1 week 1,239.1
Extreme 1239.1
1,311.75
1 month 1,131.21
Extreme 1131.21
1,311.75
Current year 850.51
Extreme 850.51
1,311.75
1 year 806.02
Extreme 806.02
1,311.75
3 years 547.61
Extreme 547.61
1,311.75
5 years 231.87
Extreme 231.87
1,311.75
10 years 64.18
Extreme 64.18
1,311.75
Manager TitleAgeSince
Chief Executive Officer 58 2016-12-31
Director of Finance/CFO 49 2024-09-08
Chief Tech/Sci/R&D Officer 52 -
Director TitleAgeSince
Director/Board Member 66 2004-12-31
Director/Board Member 70 2009-03-31
Director/Board Member 54 2011-12-11
Date Insider Type Main position Quantity % Market Cap. Importance
9/21/26 Free

Director

11 0.0000%
9/21/26 Free

Director

14 0.0000%
9/21/26 Free

Director

9 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-1.01%+5.13%+58.93%+117.36% 1,133B
-0.61%+1.52%+34.34%+68.48% 621B
-1.48%+0.47%+23.08%+94.76% 503B
-1.22%+1.90%+37.93%+62.87% 379B
+1.07%+1.70%+71.06%+45.98% 370B
+0.73%+1.46%+21.82%+51.17% 292B
+0.25%-0.54%+0.72%+25.05% 262B
-0.14%+2.87%+45.56%+57.22% 237B
-1.88%+0.02%+23.77%+97.39% 190B
+0.41%-0.28%-23.51%-61.49% 174B
Average +0.10%+3.12%+29.37%+55.88% 416.18B
Weighted average by Cap. +0.35%+3.67%+38.00%+73.75%

Financials

2026 *2027 *
Net sales 88.68B 79.03B 73.16B 66.21B 125B 8,369B 126B 877B 344B 4,399B 333B 326B 14,017B 102B 90.99B 84.25B 76.24B 144B 9,636B 145B 1,010B 396B 5,065B 383B 375B 16,140B
Net income 30.83B 27.47B 25.44B 23.02B 43.37B 2,909B 43.88B 305B 120B 1,529B 116B 113B 4,873B 40.37B 35.98B 33.31B 30.14B 56.79B 3,810B 57.46B 399B 157B 2,003B 151B 148B 6,381B
Net Debt 26.72B 23.81B 22.04B 19.95B 37.58B 2,521B 38.03B 264B 104B 1,325B 100B 98.14B 4,223B 3.3B 2.94B 2.73B 2.47B 4.65B 312B 4.7B 32.68B 12.82B 164B 12.39B 12.13B 522B
Projected Income Statement - Annual - Eli Lilly and Company
Logo Eli Lilly and Company
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (74%): products for treating osteoporosis, diabetes, and growth problems; - oncology (14.4%); - immunology diseases (8.1%); - neurology (2.1%): primarily drugs used in treating depression and schizophrenia; - other (1.4%). Net sales are distributed geographically as follows: the United States (66.7%), Europe (17.7%), Japan (3.2%), China (3%) and other (9.4%).
Employees
50,000
Date Price Change Volume
26-10-21 $1,270.75 -1.01% 1,877,165
26-10-20 $1,283.66 +3.49% 2,969,398
26-10-19 $1,240.34 -1.33% 1,960,268
26-10-16 $1,257.03 +0.43% 2,413,950
26-10-15 $1,251.61 +3.55% 3,755,241
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Eli Lilly and Company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
1,270.75USD
Average target price
1,331.55USD
Spread / Average Target
+4.78%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Eli Lilly and Company